CLINICAL TRIAL: RELAPSE PREVENTION: LONG-ACTING ATYPICAL ANTIPSYCHOTICS

临床试验：预防复发：长效非典型抗精神病药

• 批准号: 8167242
• 负责人: ALAN MENDELOWITZ
• 金额: $ 32.18万
• 依托单位: FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-04-01 至 2011-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8167242
• 关键词: Antipsychotic Agents; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Funding; Generations; Grant; Injectable; Institution; Microspheres; Oral; Patients; Pharmaceutical Preparations; Randomized; Research; Research Personnel; Resources; Risperidone; Schizoaffective Disorders; Schizophrenia; Source; United States National Institutes of Health; atypical antipsychotic; blind; disorder later incidence prevention; effectiveness trial

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The study is a multicenter, randomized, open, effectiveness trial of patients with schizophrenia or schizoaffective disorder with raters blind to treatment condition. Subjects who have had an exacerbation in the last 12 months will be randomly assigned to receive any second generation oral antipsychotic medication or the long acting injectable medication, risperidone microspheres, for a period up to 30 months of followup.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 该研究是一项针对精神分裂症或分裂情感障碍患者的多中心、随机、开放、有效性试验，评估者对治疗情况不知情。 在过去 12 个月内病情加重的受试者将被随机分配接受任何第二代口服抗精神病药物或长效注射药物利培酮微球，随访时间长达 30 个月。